Association between self-reported caffeine intake during pregnancy and social responsiveness scores in childhood: The EARLI and HOME studies.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2020
accepted:
21
12
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Maternal nutrition during gestation has been investigated for its role in child neurodevelopment. However, little is known about the potential impact of gestational caffeine exposure on child autistic behaviors. Here, we assess the relation between maternal caffeine intake during pregnancy and children's behavioral traits related to Autism Spectrum Disorder (ASD). We harmonized data from two pregnancy cohorts, Early Autism Risk Longitudinal Investigation (EARLI) (n = 120), an enriched-risk cohort of mothers who previously had a child with ASD, from Pennsylvania, Maryland, and Northern California (2009-2012), and the Health Outcomes and Measures of the Environment (HOME) Study (n = 269), a general population cohort from Cincinnati, Ohio (2003-2006). Mothers self-reported caffeine intake twice during pregnancy. Caregivers reported child behavioral traits related to ASD using the Social Responsiveness Scale (SRS) when children were aged 3-8 years. Higher scores indicate more ASD-related behaviors. We estimated covariate-adjusted differences in continuous SRS T-scores per interquartile range increase in caffeine intake. Self-reported caffeine intake during pregnancy was positively associated with SRS T-scores among children in EARLI (β: 2.0; 95% CI -0.1, 4.0), but to a lesser extent in HOME (β: 0.6; 95% CI -0.5, 1.6). In HOME, pre-pregnancy body mass index (BMI) modified the association between caffeine intake and SRS T-scores, where more positive associations were observed among women with higher BMIs. Our findings suggest gestational caffeine intake may represent a marker of vulnerability to childhood ASD-related behaviors. Additional studies are warranted to extend these findings.
Identifiants
pubmed: 33449933
doi: 10.1371/journal.pone.0245079
pii: PONE-D-20-19369
pmc: PMC7810310
doi:
Substances chimiques
Caffeine
3G6A5W338E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245079Subventions
Organisme : NIEHS NIH HHS
ID : R01 ES026903
Pays : United States
Organisme : NIEHS NIH HHS
ID : P01 ES011261
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES006096
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES014575
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES016443
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES020349
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES024381
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: JMB was financially compensated for serving as an expert witness for plaintiffs in litigation related to tobacco smoke exposures and received an honoraria for serving on an advisory panel to Quest Diagnostics. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Curr Med Chem. 2015 Feb 09;22(15):1850 - 59
pubmed: 25666800
Biol Psychiatry. 2016 Nov 1;80(9):720-726
pubmed: 26444074
Neurotoxicol Teratol. 1991 Jul-Aug;13(4):441-8
pubmed: 1921923
J Pharmacol Exp Ther. 1983 Sep;226(3):673-9
pubmed: 6887007
J Dev Behav Pediatr. 2016 Jan;37(1):1-8
pubmed: 26651088
Acta Paediatr. 2010 Jun;99(6):925-8
pubmed: 20219037
Pediatr Res. 2018 Sep;84(3):333-340
pubmed: 29983414
Sci Rep. 2017 Jun 28;7(1):4315
pubmed: 28659613
Int J Environ Res Public Health. 2016 Dec 14;13(12):
pubmed: 27983665
Res Dev Disabil. 2012 Mar-Apr;33(2):467-76
pubmed: 22119694
Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):328-34
pubmed: 18618672
Neurotoxicol Teratol. 1990 Sep-Oct;12(5):429-39
pubmed: 2247029
J Caffeine Res. 2014 Sep 1;4(3):93-99
pubmed: 25229011
Biochem Pharmacol. 1962 Feb;11:166-8
pubmed: 13899873
Neurobehav Toxicol Teratol. 1985 Sep-Oct;7(5):453-60
pubmed: 3001551
Int J Epidemiol. 2014 Apr;43(2):443-64
pubmed: 24518932
Eur J Epidemiol. 2017 Nov;32(11):1007-1017
pubmed: 28864851
J Autism Dev Disord. 2003 Aug;33(4):427-33
pubmed: 12959421
Am J Epidemiol. 1982 Oct;116(4):722-30
pubmed: 7137158
Calif J Health Promot. 2018;16(1):24-35
pubmed: 30906234
J Child Psychol Psychiatry. 2004 May;45(4):719-26
pubmed: 15056304
Epidemiology. 1991 Jul;2(4):313
pubmed: 1912049
J Nutr. 2016 Sep;146(9):1701-6
pubmed: 27489007
Food Chem Toxicol. 2004 Dec;42(12):1923-30
pubmed: 15500929
Int J Neurosci. 1988 Jul;41(1-2):15-28
pubmed: 3410649
Am J Clin Nutr. 2000 May;71(5 Suppl):1295S-303S
pubmed: 10799405
J Pediatr. 2017 Oct;189:120-127.e1
pubmed: 28732651
Neurobehav Toxicol Teratol. 1986 Jan-Feb;8(1):29-43
pubmed: 3703093
J Am Diet Assoc. 2008 Mar;108(3):553-61
pubmed: 18401922
Arch Pediatr Adolesc Med. 2009 Jan;163(1):19-26
pubmed: 19124699
JAMA. 2018 Jan 2;319(1):81-82
pubmed: 29297068
Autism. 2014 Jan;18(1):31-44
pubmed: 24019124
Environ Health Perspect. 2005 Oct;113(10):1376-80
pubmed: 16203250
Am J Epidemiol. 2006 Jun 1;163(11):1053-64
pubmed: 16624970
Behav Pharmacol. 1993 Oct;4(5):541-544
pubmed: 11224223
Dose Response. 2006 May 22;3(4):474-90
pubmed: 18648629
J Am Diet Assoc. 2005 Jan;105(1):110-3
pubmed: 15635355
Am J Health Promot. 2014 Jan-Feb;28(3):181-8
pubmed: 23875984
Int J Epidemiol. 2011 Oct;40(5):1314-28
pubmed: 21804097
Epidemiology. 1991 May;2(3):163-7
pubmed: 2054396
Peptides. 1990 Sep-Oct;11(5):927-32
pubmed: 2284203
Clin Obstet Gynecol. 1977 Jun;20(2):381-94
pubmed: 67917
Eur J Clin Pharmacol. 1981;21(2):121-6
pubmed: 7341280
Neurotoxicology. 2017 Sep;62:192-199
pubmed: 28736150
Metab Brain Dis. 2016 Oct;31(5):1071-80
pubmed: 27262967
MMWR Surveill Summ. 2020 Mar 27;69(4):1-12
pubmed: 32214087
J Child Neurol. 2014 Mar;29(3):360-7
pubmed: 23372032
Lancet. 2007 Feb 17;369(9561):578-85
pubmed: 17307104
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
J Neurodev Disord. 2012 Apr 18;4(1):7
pubmed: 22958474
Clin Toxicol. 1978;13(4):439-62
pubmed: 747904
Life Sci. 1996;58(8):701-9
pubmed: 8594320
Int J Epidemiol. 2017 Feb 1;46(1):24
pubmed: 27006352
Biol Psychiatry. 2005 Mar 15;57(6):655-60
pubmed: 15780853
Am J Epidemiol. 2015 Dec 15;182(12):1023-32
pubmed: 26585526
Addiction. 2016 Jun;111(6):1059-68
pubmed: 26750569
J Autism Dev Disord. 1994 Oct;24(5):659-85
pubmed: 7814313
Epidemiology. 1991 May;2(3):168-74
pubmed: 2054397
Am J Psychiatry. 2007 Apr;164(4):656-62
pubmed: 17403980
JAMA Pediatr. 2015 Feb;169(2):154-62
pubmed: 25485869
Int J Epidemiol. 2017 Dec 1;46(6):1836-1846
pubmed: 29040685
Am J Epidemiol. 2009 Jan 15;169(2):236-48
pubmed: 19019851
Am J Clin Nutr. 1997 Apr;65(4 Suppl):1220S-1228S; discussion 1229S-1231S
pubmed: 9094926
Handb Exp Pharmacol. 2011;(200):373-89
pubmed: 20859804
Int J Epidemiol. 2010 Oct;39(5):1383-93
pubmed: 20813861
J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1668-76
pubmed: 18030089
J Perinatol. 2014 Sep;34(9):688-92
pubmed: 24811227
Br J Nutr. 2008 May;99(5):1133-9
pubmed: 17967217
Am J Epidemiol. 2011 Aug 1;174(3):261-4; author reply 265-6
pubmed: 21749975
Int J Environ Res Public Health. 2018 Oct 26;15(11):
pubmed: 30373178
BMJ Open. 2016 Dec 5;6(12):e012749
pubmed: 27920084
Acta Paediatr. 2009 Jan;98(1):173-9
pubmed: 18764862